Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06694298 | A Study of SYS6020 Injection in Refractory Active Systemic Lupus Erythematosus | PHASE1 | NOT YET_RECRUITING | 50 | — | — | Dec 26, 2024 | Jan 29, 2029 | Nov 19, 2024 | - | — |
Assess safety and tolerability of SYS6020 in patients with systemic lupus erythematosus
Proportion of participants who achieved systemic lupus erythematosus remission (DORIS) at 6 months.
| Arm | Type | Description |
|---|---|---|
| SYS6020 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| SYS6020 | DRUG | BCMA Chimeric Antigen Receptor T Cell（SYS6020）Injection Intravenous infusion |
Inclusion Criteria: * 1\. Age ≥18 years old, ≤70 years old; * 2\. SLE is diagnosed according to SLICC 2012 or EULAR/ACR 2019 revised criteria. * 3\. Patients are required to have received glucocorticoid combined with immunosuppressive agents and/or biological agents for more than 3 months, with a s...